Trilogy Capital Inc. Gilead Sciences, Inc. Transaction History

Trilogy Capital Inc.

$1.81 Billion
Q2 2024

A detailed history of Trilogy Capital Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Trilogy Capital Inc. holds 41,307 shares of GILD stock, worth $3.47 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

41,307

Previous 38,116 8.37%

Holding current value

$3.47 Million

Previous $2.79 Million 1.54%

% of portfolio

0.16%

Previous 0.16%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 22, 2024	BUY	$63.15 - $72.88 $201,511 - $232,560	3,191 Added 8.37%	41,307 $2.83 Million
Q1 2024 Apr 17, 2024	BUY	$71.58 - $87.29 $2.38 Million - $2.9 Million	33,202 Added 675.66%	38,116 $2.79 Million
Q4 2023 Jan 11, 2024	SELL	$73.27 - $83.09 $33,557 - $38,055	-458 Reduced 8.53%	4,914 $398,000
Q3 2023 Oct 16, 2023	SELL	$73.94 - $80.67 $30,980 - $33,800	-419 Reduced 7.24%	5,372 $402,000
Q2 2023 Jul 24, 2023	BUY	$76.01 - $86.7 $56,399 - $64,331	742 Added 14.7%	5,791 $446,000
Q1 2023 Apr 17, 2023	SELL	$77.31 - $88.08 $1.8 Million - $2.05 Million	-23,304 Reduced 82.19%	5,049 $418,000
Q4 2022 Feb 09, 2023	SELL	$62.32 - $89.47 $162,156 - $232,800	-2,602 Reduced 8.41%	28,353 $2.43 Million
Q3 2022 Oct 21, 2022	BUY	$59.54 - $68.01 $216,249 - $247,012	3,632 Added 13.29%	30,955 $1.91 Million
Q2 2022 Jul 20, 2022	BUY	$57.72 - $65.01 $350,879 - $395,195	6,079 Added 28.62%	27,323 $1.69 Million
Q1 2022 Apr 08, 2022	BUY	$57.92 - $72.58 $248,129 - $310,932	4,284 Added 25.26%	21,244 $1.26 Million
Q4 2021 Jan 18, 2022	BUY	$64.88 - $73.64 $49,114 - $55,745	757 Added 4.67%	16,960 $1.23 Million
Q3 2021 Oct 15, 2021	BUY	$67.69 - $73.03 $1,286 - $1,387	19 Added 0.12%	16,203 $1.13 Million
Q2 2021 Jul 14, 2021	BUY	$63.47 - $69.35 $401,003 - $438,153	6,318 Added 64.04%	16,184 $1.1 Million
Q1 2021 Apr 12, 2021	BUY	$60.0 - $68.46 $44,460 - $50,728	741 Added 8.12%	9,866 $638,000
Q4 2020 Feb 05, 2021	BUY	$56.65 - $64.55 $2,605 - $2,969	46 Added 0.51%	9,125 $532,000
Q3 2020 Nov 16, 2020	SELL	$62.1 - $78.08 $22,356 - $28,108	-360 Reduced 3.81%	9,079 $574,000
Q2 2020 Jul 22, 2020	BUY	$72.34 - $84.0 $106,556 - $123,732	1,473 Added 18.49%	9,439 $737,000
Q1 2020 Apr 28, 2020	BUY	$62.63 - $80.22 $498,910 - $639,032	7,966 New	7,966 $637,000
Q1 2019 Apr 17, 2019	SELL	$62.53 - $70.05 $244,054 - $273,405	-3,903 Closed	0 $0
Q4 2018 Jan 15, 2019	SELL	$60.54 - $79.0 $207,470 - $270,733	-3,427 Reduced 46.75%	3,903 $244,000
Q3 2018 Oct 31, 2018	SELL	$71.28 - $78.92 $60,160 - $66,608	-844 Reduced 10.33%	7,330 $566,000
Q2 2018 Aug 20, 2018	SELL	$64.88 - $75.68 $30,363 - $35,418	-468 Reduced 5.42%	8,174 $579,000
Q1 2018 May 24, 2018	BUY	$72.84 - $88.8 $629,483 - $767,409	8,642 New	8,642 $652,000

Others Institutions Holding GILD

# of Institutions

1,878

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Trilogy Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Trilogy Capital Inc. with notifications on news.

Account

Trilogy Capital Inc. Gilead Sciences, Inc. Transaction History